Stock A208340 PHARMABCINE INC.
Add to a list
To use this feature you must be a member
Log inSign up

PharmAbcine Inc. Stock

Equities

A208340

KR7208340000

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-01-18 pm EST 		5-day change 1st Jan Change
2,915 KRW -8.91% Intraday chart for PharmAbcine Inc. -.--% -22.27%
Jan. 24 PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors CI
2023 PharmAbcine Inc. announced that it has received KRW 5.000000492 billion in funding CI

Financials

Sales 2022 207M 151K Sales 2023 74.96M 54.87K Capitalization 98.18B 71.87M
Net income 2022 -30.55B -22.36M Net income 2023 -14.25B -10.43M EV / Sales 2022 316 x
Net cash position 2022 11.16B 8.17M Net cash position 2023 13.24B 9.69M EV / Sales 2023 1,133 x
P/E ratio 2022
-2.5 x
P/E ratio 2023
-6.82 x
Employees 44
Yield 2022 *
-
Yield 2023
-
Free-Float 98.52%
More Fundamentals * Assessed data

Chart PharmAbcine Inc.

Dynamic Chart

Latest news about PharmAbcine Inc.

PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors CI
PharmAbcine Inc. announced that it has received KRW 5.000000492 billion in funding CI
PharmAbcine Inc. announced that it has received KRW 30.000001149 billion in funding from Hpbiolab Inc. CI
Pharmabcine, Inc. Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-Related Macular Degeneration Following Dose Level 1 Safety Data CI
PharmAbcine Inc. announced that it expects to receive KRW 5.000000492 billion in funding CI
PharmAbcine Inc. announced extension to the offering period CI
Yukon Partners Co., Ltd. acquired a 6.2% stake in PharmAbcine Inc. from Yoo Jin San for KRW 4.4 billion CI
PharmAbcine Inc. announced that it expects to receive KRW 30.000001149 billion in funding CI
PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of its Novel TIE2 Agonistic Antibody in nAMD CI
PharmAbcine Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Pharmabcine Announces Collaboration Agreement with MSD to Evaluate Anti-Vista Antibody PMC-309 in Combination with Keytruda(R) (Pembrolizumab) CI
PharmAbcine Inc.(KOSDAQ:A208340) dropped from S&P Global BMI Index CI
Pharmabcine Inc. Announces the Positive Results from the GLP Toxicology Study of PMC-403, the Company's Novel TIE2-Activating Antibody CI
PharmAbcine Inc. Announces the Appointment of Quan Dong Nguyen to its Scientific Advisory Board CI
PharmAbcine Inc. announced that it has received KRW 10 billion in funding from Kiwoom Asset Management Co., Ltd., Hanyang Securities Co. Ltd., NH Investment & Securities Co., Ltd., Investment Arm CI
More news

Press releases PharmAbcine Inc.

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology Annual Meeting 2024 AQ
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA in Patients with Advanced or Metastatic Solid Tumors AQ
PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data AQ
PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase 2023 during JPM Week AQ
More press releases

Quotes and Performance

1 day-8.91%
6 months+130.98%
Current year-22.27%
More quotes

Highs and lows

Current year
2 315.00
Extreme 2315
3 970.00
1 year
900.00
Extreme 900
4 630.00
3 years
900.00
Extreme 900
13 200.00
5 years
900.00
Extreme 900
31 000.00
10 years
900.00
Extreme 900
37 480.00
More quotes

Managers and Directors - PharmAbcine Inc.

Managers TitleAgeSince
Jin-San Yoo FOU
 Founder 61 08-08-31
Chul-Bum Kim DFI
 Director of Finance/CFO 59 -
Hyun-Seon Park COO
 Chief Operating Officer 61 18-12-31
Members of the board TitleAgeSince
Chul-Bum Kim DFI
 Director of Finance/CFO 59 -
Jin-San Yoo FOU
 Founder 61 08-08-31
Won-Sub Lee CTO
 Chief Tech/Sci/R&D Officer 55 07-12-31
More insiders

Company Profile

PharmAbcine Inc. is a Korea-based company mainly engaged in the research and development of biopharmaceuticals. The Company researching and developing antibody therapeutics to provide patients with the antibodies needed to cure the disease. The Company’s major products include tanibirumab used for cancer treatment, among others. The Company also carries out technology transfer about its pipelines with domestic and overseas pharmaceutical companies.
Sector
Biotechnology & Medical Research
Calendar
2024-05-06 - Association for Research in Vision and Ophthalmology Conference - Presentation Number: 2159
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PHARMABCINE INC. Stock PharmAbcine Inc.
-22.27% 63.6M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.67% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+6.79% 97.47B
ARGENX SE Stock argenx SE
+5.71% 22.25B
BIONTECH SE Stock BioNTech SE
-12.58% 21.68B
GENMAB A/S Stock Genmab A/S
-9.70% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.14% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.99% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.79% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A208340 Stock